Description: IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States and Europe. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations without the need for highly specialized informatics professionals, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.
Home Page: isoplexis.com
ISO Technical Analysis
35 NE Industrial Road
Branford,
CT
06405
United States
Phone:
203 208 4111
Officers
| Name | Title |
|---|---|
| Mr. Sean Mackay | Co-Founder, CEO, Pres & Director |
| Mr. John R. Strahley CPA | Chief Financial Officer |
| Mr. Rong Fan | Co-Founder & Chairman of Scientific Advisory Board |
| Mr. Jon Chen | VP of Scientific Alliance Technology & Co-Founder |
| Mr. Anthony Catalano | Sr. VP of Operations |
| Mr. Rajesh T. Khakhar | VP of Fin. & Principal Accounting Officer |
| Ms. Jing Zhou M.D., Ph.D. | Chief Scientific Officer |
| Mr. Richard W. Rew II | Sr. VP, Gen. Counsel & Sec. |
| Ms. Verna Siu | Sr. VP of Sales Operations |
| Ms. Carrie Carter | Sr. VP of People Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.1593 |
| Price-to-Book MRQ: | 0.4792 |
| Price-to-Sales TTM: | 1.5676 |
| IPO Date: | 2021-10-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 459 |